Peptide Library

Human study PLS-00210

A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds

Other design · 12 participants enrolled

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Woundsregistry entry · NCT00598871 (TERMINATED, results posted, planned enrollment 12)

Design and participants

Design
Other design
Population
People with corneal wounds; the registered condition is diabetes. Eligibility details are not stated in the record.
Conditions
Corneal wounds, Diabetes
Planned enrollment (registry)
12
Enrolled
12
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

  • Thymosin beta 4 eye drops (RGN-259) (intervention) · thymosin-beta-4 · Thymosin beta 4 ophthalmic eye drops, also listed as RGN-259 · topical ocular (eye drops) · Not reported assigned
  • Placebo (comparator) · Placebo listed as an intervention in the registry · placebo · Not reported assigned

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety.

Monitoring: The title says the study assessed safety. The record gives no safety monitoring methods.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

  • abstract only: Only the registry entry is available. It gives no outcome definitions, results or adverse event data, even though it is flagged as having results.
  • small or imprecise: Only 12 participants were actually enrolled, which is too few for precise estimates of efficacy or safety.
  • other: The record does not say whether allocation to thymosin beta 4 or placebo was randomized, so the design cannot be confirmed as an RCT.
  • inappropriate population: The population is people with diabetes and corneal wounds, not dry eye disease.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

  • Insufficient information to assess Adverse events, serious adverse events and discontinuations

Where each value comes from

  • arms: NCT NCT00598871, registry (interventions field) · extracted by AI (automated, not verified by a person)
  • design: NCT NCT00598871, registry (phases, study_type and interventions fields) · extracted by AI (automated, not verified by a person)
  • limitations: NCT NCT00598871, registry (status, enrollment and has_results fields) · extracted by AI (automated, not verified by a person)
  • participants: NCT NCT00598871, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
  • population: NCT NCT00598871, title (study title; registry conditions field) · extracted by AI (automated, not verified by a person)

  • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).